Adherex Technologies (NASDAQ:FENC – Get Free Report) and Sanofi (NASDAQ:SNY – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.
Volatility and Risk
Adherex Technologies has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.
Insider & Institutional Ownership
55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Adherex Technologies and Sanofi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adherex Technologies | -6.09% | -5.71% | -2.37% |
| Sanofi | 8.70% | 15.16% | 8.48% |
Valuation & Earnings
This table compares Adherex Technologies and Sanofi”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adherex Technologies | $44.64 million | 8.54 | -$9.74 million | ($0.13) | -83.31 |
| Sanofi | $49.35 billion | 2.36 | $8.84 billion | $2.02 | 23.82 |
Sanofi has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and recommmendations for Adherex Technologies and Sanofi, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adherex Technologies | 1 | 1 | 4 | 0 | 2.50 |
| Sanofi | 0 | 12 | 8 | 1 | 2.48 |
Adherex Technologies presently has a consensus price target of $17.00, indicating a potential upside of 56.97%. Sanofi has a consensus price target of $53.00, indicating a potential upside of 10.14%. Given Adherex Technologies’ stronger consensus rating and higher possible upside, research analysts plainly believe Adherex Technologies is more favorable than Sanofi.
Summary
Sanofi beats Adherex Technologies on 8 of the 14 factors compared between the two stocks.
About Adherex Technologies
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
